Pulse Biosciences filings document regulatory disclosures for a Delaware medical technology company developing nPulse nanosecond pulsed field ablation technology. Its 8-K reports cover clinical and Regulation FD disclosures for the nPulse Cardiac Catheter System, atrial fibrillation study updates, investor presentation materials, and development priorities in electrophysiology, cardiac surgery, and soft tissue ablation.
The company's SEC record also includes proxy materials on board governance, executive compensation, equity awards, and shareholder voting matters. Other filings address capital structure, common stock financing arrangements, officer appointments, compensatory arrangements, operating and financial results, ownership matters, and risk factors tied to its technology development and clinical regulatory activities.
Pulse Biosciences, Inc. filed an 8-K after announcing first patient enrollments in a multi-center, first-in-human feasibility study of its nPulse Vybrance Percutaneous Electrode System for treating T1N0M0 papillary thyroid microcarcinoma, a common low-risk thyroid cancer. Initial procedures were successfully completed at Sarasota Memorial Health Care System in Florida and The University of Texas MD Anderson Cancer Center in Texas.
The study plans to enroll 30 patients with tumors under 1.5 cm to evaluate the safety and effectiveness of the Vybrance System, which uses Nanosecond Pulsed Field Ablation (nsPFA) to nonthermally remove cellular tissue while sparing surrounding structures. The system already holds FDA 510(k) clearance for soft tissue ablation and is now being evaluated under an Investigational Device Exemption specifically for thyroid cancer, with the study funded in part by the company.
Pulse Biosciences filed an 8-K to share new long-term clinical data from its nPulse Vybrance Percutaneous Electrode System first-in-human feasibility study for benign thyroid nodules using nsPFA energy. The extension study followed 21 patients for 15–22 months to assess durability of treatment effects.
The company reports an average 74% volume reduction in treated benign thyroid nodules, with no nodule regrowth observed during follow-up and no serious adverse events. Patient-reported outcomes were very strong: 100% of patients were highly satisfied with cosmetic results and 95% were highly satisfied overall at final follow-up, supporting the potential durability and tolerability of this nonthermal ablation approach.
Pulse Biosciences, Inc. furnished an updated investor presentation dated March 2026, which has been posted on its website and attached as Exhibit 99.1. The deck includes summary financial information, details on the next-generation nPulse cardiac catheter under development, and an increased focus on EP cardio ablation products and clinical development following what it describes as unprecedented clinical outcomes data from its EU feasibility study.
The company plans to use this investor presentation, in whole or in part and potentially with modifications, in meetings with investors, analysts, and others. The information is provided under a Reg FD disclosure, is considered "furnished" rather than "filed," and includes forward-looking statements that are subject to risks and uncertainties referenced in the company’s SEC filings.
Pulse Biosciences, Inc. filed an amended current report to update a prior disclosure about a leadership change. The amendment notes that on February 27, 2026, Chief Commercial Officer Kevin P. Danahy notified the company that he was resigning, effective immediately. The amended report states it was filed to remove two sentences from the original filing, but does not change the core fact of his immediate departure. The company continues to be led by President and Chief Executive Officer Paul A. LaViolette, who signed the report.
Pulse Biosciences, Inc. reported that its Chief Commercial Officer, Kevin P. Danahy, resigned from the company effective immediately on February 27, 2026. The company stated that his resignation was not due to any disagreement regarding operations, policies, practices, or accounting matters.
The filing notes that Mr. Danahy played an important role in senior management and in the company’s early commercialization efforts, and extends well wishes for his future endeavors.
PULSE BIOSCIENCES, INC. Chief Commercial Officer Kevin Patrick Danahy exercised options and sold shares on February 18, 2026 under a pre‑arranged Rule 10b5‑1 trading plan adopted on May 14, 2025.
He exercised stock options for 5,000 shares at an exercise price of $1.53 per share and received 5,000 shares of common stock. He then sold 5,000 common shares in the open market at a weighted average price of $23.64 per share, with individual sale prices ranging from $22.40 to $24.40. After these transactions, he directly owned 43,298 common shares and held 300,000 stock options.
Pulse Biosciences, Inc. reported early commercial revenue and higher operating losses as it advances its nPulse nanosecond PFA platform. Fourth quarter 2025 revenue was $264 thousand, up from $86 thousand in the prior quarter, and full-year 2025 revenue reached $350 thousand.
GAAP costs and expenses for 2025 were $77.3 million, up from $56.3 million, driving a GAAP net loss of $72.8 million versus $53.6 million a year earlier. Non-GAAP net loss rose to $50.8 million from $36.9 million. Cash and cash equivalents were $80.7 million as of December 31, 2025, down from $118.0 million a year earlier.
The company highlighted strong feasibility data in atrial fibrillation, with 100% procedural success at six months and 96% at one year in evaluable patients treated with the nPulse Cardiac Catheter System. It received FDA approval to commence a pivotal IDE study in paroxysmal AF, is running the NANOCLAMP AF surgical IDE pivotal study, and is expanding soft tissue ablation efforts, including a collaboration with MD Anderson for thyroid tumors.
Pulse Biosciences, Inc. filed a shelf registration to offer up to $200,000,000 of securities. The registration permits the sale, from time to time, of common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts and units under a prospectus dated February 19, 2026.
The prospectus states offerings will be made by prospectus supplement describing amounts, prices and terms, and notes the company’s common stock trades on the Nasdaq Capital Market under the symbol PLSE; the last reported sale price on February 18, 2026 was $25.46.
Pulse Biosciences, Inc. entered into a sales agreement with TD Securities (USA) LLC to sell up to $59,976,196 of its common stock in an at-the-market offering under a shelf registration.
The supplement states the offering may be made from time to time through TD Cowen, that TD Cowen will act as sales agent for up to $59,976,196, and that compensation to TD Cowen may be up to 3% of gross proceeds. Shares outstanding used for illustrative dilution are 67,839,689 as of December 31, 2025.
Pulse Biosciences, Inc. entered into a new equity distribution agreement with TD Securities (USA) LLC, allowing the company to sell, from time to time, shares of common stock with an aggregate offering price of up to $59,976,196 in at-the-market transactions. TD Cowen will act as sales agent and receive a commission of up to 3.0% of the gross sales price of shares sold, plus specified expense reimbursements. The shares will be issued under existing effective shelf registration statements and a prospectus supplement filed on February 19, 2026. On February 18, 2026, the company terminated its prior at-the-market program, under which the same aggregate amount of common stock remained unsold.